Lumos Pharma Stock Cash Per Share
Lumos Pharma fundamentals help investors to digest information that contributes to Lumos Pharma's financial success or failures. It also enables traders to predict the movement of Lumos Stock. The fundamental analysis module provides a way to measure Lumos Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lumos Pharma stock.
Lumos |
Lumos Pharma Company Cash Per Share Analysis
Lumos Pharma's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Lumos Pharma Cash Per Share | 9.49 X |
Most of Lumos Pharma's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lumos Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Lumos Pharma has a Cash Per Share of 9.49 times. This is 118.16% higher than that of the Biotechnology sector and 119.17% higher than that of the Health Care industry. The cash per share for all United States stocks is 89.42% lower than that of the firm.
Lumos Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lumos Pharma's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lumos Pharma could also be used in its relative valuation, which is a method of valuing Lumos Pharma by comparing valuation metrics of similar companies.Lumos Pharma is currently under evaluation in cash per share category among its peers.
Lumos Fundamentals
Return On Equity | -1.73 | |||
Return On Asset | -0.7 | |||
Operating Margin | (10.52) % | |||
Current Valuation | 24.19 M | |||
Shares Outstanding | 8.65 M | |||
Shares Owned By Insiders | 32.69 % | |||
Shares Owned By Institutions | 24.27 % | |||
Number Of Shares Shorted | 54.33 K | |||
Price To Earning | (2.37) X | |||
Price To Book | 7.64 X | |||
Price To Sales | 17.02 X | |||
Revenue | 2.05 M | |||
Gross Profit | 1.52 M | |||
EBITDA | (36.57 M) | |||
Net Income | (34.03 M) | |||
Cash And Equivalents | 79.51 M | |||
Cash Per Share | 9.49 X | |||
Total Debt | 585 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 17.59 X | |||
Book Value Per Share | 0.57 X | |||
Cash Flow From Operations | (31.09 M) | |||
Short Ratio | 0.59 X | |||
Earnings Per Share | (4.28) X | |||
Price To Earnings To Growth | (0.15) X | |||
Target Price | 4.25 | |||
Number Of Employees | 30 | |||
Beta | 0.33 | |||
Market Capitalization | 37.54 M | |||
Total Asset | 40.64 M | |||
Retained Earnings | (161.52 M) | |||
Working Capital | 33.01 M | |||
Current Asset | 115.78 M | |||
Current Liabilities | 14.4 M | |||
Net Asset | 40.64 M |
Pair Trading with Lumos Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lumos Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lumos Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to CMS Energy could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CMS Energy when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CMS Energy - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CMS Energy to buy it.
The correlation of CMS Energy is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CMS Energy moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CMS Energy moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CMS Energy can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Lumos Stock
If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |